The outcome of advanced and recurrent cervical cancer patients treated with first-line platinum and paclitaxel with or without indication for immune checkpoint inhibitors: the comparative study
First-line ICI plus platinum and paclitaxel yields better treatment responses, longer survival, and non-differential adverse events versus first-line platinum and paclitaxel in advanced and recurrent cervical cancer patients.
Authors
- Haiyan Wu (ORCID: https://orcid.org/0000-0001-8869-6636)
- Feng Lan (ORCID: https://orcid.org/0000-0002-1709-5179)
- Qun Shi (ORCID: https://orcid.org/0009-0006-1931-8096)
- Wei Lei (ORCID: https://orcid.org/0000-0001-8498-7161)
- Jing Zhang (ORCID: https://orcid.org/0000-0002-2488-5021)
- Dan Zhang (ORCID: https://orcid.org/0000-0003-0122-5036)
- Shujuan Wang (ORCID: https://orcid.org/0000-0003-4062-3096)
- Qing Hao
- Xinxin Zhan
- Jingwen Jiang (ORCID: https://orcid.org/0000-0002-1917-1841)
- Zhaojun Cui
- Ye Zhao
Institutions
- Hebei Medical University (CN)
- Xingtai People's Hospital (CN)
- First Hospital of Shijiazhuang (CN)
- Xian Yang Central Hospital (CN)
- Pingliang People's Hospital (CN)
- Xingtai Medical College
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1186/s12885-024-12989-x
- Citations
- 2
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.17